Streetbeat News

Products Services

CORT

Corcept Therapeutics announced results from the CATALYST clinical trial at the ADA's 84th Scientific Sessions, showing a 24% prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. The study, involving 1,055 patients, is the largest of its kind.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:17 pm

RIGL

Rigel Pharmaceuticals has completed the transfer of the New Drug Application for GAVRETO, a treatment for certain types of cancer. GAVRETO will be available in the U.S. starting June 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:11 pm

ABG

Asbury Automotive Group (NYSE:ABG) has been impacted by a cyber-attack on its vendor, CDK Global, affecting various business operations. While contingency plans are in place, some business functions may operate slower than usual. Koons Automotive locations and Clicklane remain minimally affected.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:10 pm

FBIN

Moen has announced a partnership with Amica Insurance to promote the adoption of Flo Smart Water Monitor and Shutoff devices. The initiative aims to reduce water damage and preventable flooding, with the devices capable of lowering water damage claims by 96% and preventable leaks by 90%.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:10 pm

GRAL

ILMN

GRAIL, Inc. (NASDAQ:GRAL) will commence regular-way trading on the Nasdaq Global Select Market starting June 25, 2024, following its spin-off from Illumina (NASDAQ:ILMN). GRAIL focuses on developing groundbreaking cancer screening technology.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:08 pm

GRAL

ILMN

GRAIL, Inc. (NASDAQ:GRAL) will begin trading on the Nasdaq Global Select Market on June 25, 2024, following its spin-off from Illumina (NASDAQ:ILMN). GRAIL focuses on developing groundbreaking cancer screening technology.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:08 pm

FAAS

NVDA

Digi Tech has secured an allocation of 5,120 NVIDIA H200 GPUs to enhance its AI solutions for the fintech, telecom, and government sectors. The initial deployment is expected in Q4 2024, with plans for global expansion leveraging the Dubai International Financial Center. The market opportunity is estimated at $200-300 billion annually in financial services, with significant growth anticipated from Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:06 pm

WOLF

Wolfspeed, Inc. (NYSE: WOLF) announced key milestones and an operational update. The Mohawk Valley 200mm Silicon Carbide Fab has reached 20% utilization and achieved LEED certification. The company also reported a temporary impact from an equipment incident at its Durham 150mm Device Fab.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:06 pm

VTVT

vTv Therapeutics has screened the first patient in its CATT1 pivotal trial for Cadisegliatin, a potential first-in-class oral liver selective glucokinase activator for Type 1 Diabetes (T1D). The drug has been granted Breakthrough Therapy designation by the FDA and has been dosed in over 500 subjects, including 300 patients with diabetes.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 8:05 pm

PRAX

Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX) with a Buy rating and a price target of $145. The company's lead product, ulixacaltamide, is in Phase 3 trials for essential tremor, with results expected in the second half of 2024. If successful, sales could peak at over $1 billion by 2030. Praxis also has other promising programs, including PRAX-628 for focal onset seizures and PRAX-562 for developmental and epileptic encephalopathies. The company's cash runway extends into 2027.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 7:54 pm